Storyline
FDA expands approval of Rhythm Pharma's Imcivree to acquired hypothalamic obesity
Rhythm Pharma's Imcivree has received FDA approval for acquired hypothalamic obesity, marking the first drug approved for this brain injury-driven form of obesity.
Evidence locked
Today's free sample is only available for the edition's flagship storyline.
Evidence preview
- BioPharma Divebiopharmadive.com
- The new FDA nod makes Rhythm Pharma's Imcivree the first approved drug for acquired hypothalamic obesity and brings t...Fierce Pharma (All)
- After setback, Rhythm gets good news on Imcivree from FDApharmaphorum